We're pleased to announce that Scan.com has closed $220 million in combined equity and debt financing, following a year in which the company doubled revenue to surpass a $165 million annualised run rate.
The $90 million equity round was led by Noteus Partners, with participation from Aviva, Concord Health Partners, YZR Capital, Oxford Capital and others. A further $130 million of debt facilities supporting M&A and working capital were provided by VerisFi Capital and Atempo Growth.
The problem
Nearly two million patients in the UK are currently waiting for diagnostic tests, and almost half of NHS trusts are missing their six-week wait target. Patients face waits averaging six to twelve weeks. Faced with this, more patients are going elsewhere: over 1.1 million private diagnostic tests and scans were delivered in 2024 alone, a double-digit increase on the previous year, in a UK diagnostic imaging market now worth £10.7 billion. To be clear: these are not lifestyle checks. Almost half of scans among patients aged 30 to 59 relate to chronic pain or musculoskeletal problems, where imaging determines what happens next.
But a scan on its own isn't an answer. A patient who self-refers into private imaging without a clinical framework around it can end up in limbo: a report in hand, no onward route, with no clear way back into NHS treatment.
Slow access on one side, no follow-through on the other: that gap is the diagnostic black hole, and it isn't a capacity problem that more scanners will fix. It's a pathway problem.
The solution Scan.com provides
Scan.com was built to deliver a tech-enabled, digital pathway, not just the scan. Every referral is triaged: a clinician speaks to the patient before they are scanned, so the scan is clinically appropriate and the correct scan for the patient’s needs.
Imaging centres receive a referral that is ready to go. Reports are returned by qualified radiologists, and where results point to onward care, Scan.com flags it, so the next step doesn't depend on the patient chasing a letter. Internal data shows between 20% and 30% were referred on to a specialist following their scan.
That pathway is what the funding helps scale. Building more capacity across the independent centres and hospital groups Scan.com already works with, faster routes from referral to appointment, and closer integration with the partners across the network, so that more patients get the right scan, quickly and a clear route to whatever comes next.
"Our growth over the last year shows that we do works, said Dr. Lizzie Tuckey, Managing Director of Scan.com. "It shows that private imaging done well isn't an end-run around clinical governance. It's an extension of it. We started in the UK in 2017 because two clinicians were tired of watching their own patients wait weeks and months for a scan, and nine years on we're the country's largest independent medical imaging network. The UK is where the model was proved, and it's where we'll keep investing in the network and the partners who built it with us. The ambition hasn't changed since 2017. Every patient deserves timely, affordable access to imaging, and a clear route to whatever comes next."
Scaling globally
Scan.com expanded into the United States in 2023 and now has operations live nationwide, where more than 900,000 patients have accessed care through the network globally. The American market has the same disconnect on a larger scale: patients waiting weeks, the same study costing several times more at one centre than another a few miles away, and nothing linking a patient to the right scanner at the right time.
Where similar companies rely on static provider directories, Scan.com integrates live and two-way with imaging centres' own scheduling systems and electronic medical records. Employers, health plans, third-party administrators and digital health platforms connect to imaging capacity nationwide through a single API.
The funding will expand Scan.com's network of imaging providers across the United States and fund continued investment in the infrastructure that routes patients, schedules scans and returns results. The company will continue to invest in the UK network and its referral partners alongside that expansion.
"We're pleased to continue our early support of Scan.com, one of the UK's most exciting healthtech firms, through this Series C round. UK pension funds increasingly want greater access to high-growth, unlisted companies that build tomorrow's technologies and create social value - in Scan.com's case, through faster access to private imaging and diagnostics. It's one of the fastest-growing companies in our venture capital portfolio, and well placed to deliver long-term returns for UK savers and institutional investors, in line with our Mansion House Compact objectives," said Anthony Barker, Director of Venture Capital at Aviva Investors.
For media enquiries, please contact [email protected]
